Drugmaker Medivation (MDVN) agreed to acquire a late-stage breast-cancer drug candidate from BioMarin Pharmaceutical (BMRN) Monday in a deal worth up to $570 million. Medivation is paying $410 million upfront for talazoparib, which is currently in phase three testing for advanced or metastatic breast cancer involving germline mutations of the BRCA gene. If the drug succeeds, BioMarin is due up to $160 million in milestone payments along with
Halozyme Therapeutics has been one of 2015’s hotter biotech stocks, but it’s not exactly because of developing a drug. Halozyme’s (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanz for the same purpose to such drug companies as Pfizer (PFE), Roche (RHHBY), Johnson & Johnson ‘s (JNJ) Janssen division, AbbVie (ABBV) and Baxalta (BXLT) for the development of new injectable products. San
Can Workday (WDAY) keep the streak alive? The provider of human capital management software has beaten Wall Street estimates on both revenue and earnings for each of the last eight quarters. That streak will be on the line when it reports fiscal 2016 second-quarter results on Wednesday. The company is expected to post another deficit, this time a loss of 6 cents a share, excluding items, in the report. Regardless of whether it pleasantly surprises